In June 2024, the biopharma industry witnessed a high-stakes dance of negotiation, as Regulus Therapeutics successfully played the field to license its promising Phase Ib trial drug, farabursen, an innovative therapy for autosomal dominant polycystic kidney disease (ADPKD). The strategic maneuvers and back-and-forth exchanges underscored the fierce nature of biopharma deal-making, providing a window into […]